SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD - News), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the company will present preclinical data on its two advanced schizophrenia programs at the 37th Annual Meeting of the Society for Neuroscience to be held in San Diego, California from November 2-5, 2007.
